Literature DB >> 33188449

Role of actin cytoskeleton in podocytes.

Sanja Sever1.   

Abstract

The selectivity of the glomerular filter is established by physical, chemical, and signaling interplay among its three core constituents: glomerular endothelial cells, the glomerular basement membrane, and podocytes. Functional impairment or injury of any of these three components can lead to proteinuria. Podocytes are injured in many forms of human and experimental glomerular disease, including minimal change disease, focal segmental glomerulosclerosis, and diabetes mellitus. One of the earliest signs of podocyte injury is loss of their distinct structure, which is driven by dysregulated dynamics of the actin cytoskeleton. The status of the actin cytoskeleton in podocytes depends on a set of actin binding proteins, nucleators and inhibitors of actin polymerization, and regulatory GTPases. Mutations that alter protein function in each category have been implicated in glomerular diseases in humans and animal models. In addition, a growing body of studies suggest that pharmacological modifications of the actin cytoskeleton have the potential to become novel therapeutics for podocyte-dependent chronic kidney diseases. This review presents an overview of the essential proteins that establish actin cytoskeleton in podocytes and studies demonstrating the feasibility of drugging actin cytoskeleton in kidney diseases.
© 2020. IPNA.

Entities:  

Keywords:  Actin binding proteins (ABPs); Actin cytoskeleton; Glomerular diseases; Nucleators of actin polymerization; Podocytes; Regulatory GTPases

Mesh:

Year:  2020        PMID: 33188449      PMCID: PMC8116355          DOI: 10.1007/s00467-020-04812-z

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.651


  60 in total

1.  Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease.

Authors:  Sanja Sever; Mehmet M Altintas; Sharif R Nankoe; Clemens C Möller; David Ko; Changli Wei; Joel Henderson; Elizabetta C del Re; Lianne Hsing; Ann Erickson; Clemens D Cohen; Matthias Kretzler; Dontscho Kerjaschki; Alexander Rudensky; Boris Nikolic; Jochen Reiser
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

2.  MYO1E mutations and childhood familial focal segmental glomerulosclerosis.

Authors:  Caterina Mele; Paraskevas Iatropoulos; Roberta Donadelli; Andrea Calabria; Ramona Maranta; Paola Cassis; Simona Buelli; Susanna Tomasoni; Rossella Piras; Mira Krendel; Serena Bettoni; Marina Morigi; Massimo Delledonne; Carmine Pecoraro; Isabella Abbate; Maria Rosaria Capobianchi; Friedhelm Hildebrandt; Edgar Otto; Franz Schaefer; Fabio Macciardi; Fatih Ozaltin; Sevinc Emre; Tulin Ibsirlioglu; Ariela Benigni; Giuseppe Remuzzi; Marina Noris
Journal:  N Engl J Med       Date:  2011-07-14       Impact factor: 91.245

3.  The Rho-GTPase binding protein IQGAP2 is required for the glomerular filtration barrier.

Authors:  Yuya Sugano; Maja T Lindenmeyer; Ines Auberger; Urs Ziegler; Stephan Segerer; Clemens D Cohen; Stephan C F Neuhauss; Johannes Loffing
Journal:  Kidney Int       Date:  2015-07-08       Impact factor: 10.612

4.  Structural Insights into the Induced-fit Inhibition of Fascin by a Small-Molecule Inhibitor.

Authors:  Jianyun Huang; Raja Dey; Yufeng Wang; Jean Jakoncic; Igor Kurinov; Xin-Yun Huang
Journal:  J Mol Biol       Date:  2018-03-21       Impact factor: 5.469

5.  Podocyte-specific deletion of Myh9 encoding nonmuscle myosin heavy chain 2A predisposes mice to glomerulopathy.

Authors:  Duncan B Johnstone; Jidong Zhang; Britta George; Catherine Léon; Christian Gachet; Hetty Wong; Rulan Parekh; Lawrence B Holzman
Journal:  Mol Cell Biol       Date:  2011-03-14       Impact factor: 4.272

6.  Crystal structure of the dynamin tetramer.

Authors:  Thomas F Reubold; Katja Faelber; Nuria Plattner; York Posor; Katharina Ketel; Ute Curth; Jeanette Schlegel; Roopsee Anand; Dietmar J Manstein; Frank Noé; Volker Haucke; Oliver Daumke; Susanne Eschenburg
Journal:  Nature       Date:  2015-08-24       Impact factor: 49.962

7.  A Podocyte-Based Automated Screening Assay Identifies Protective Small Molecules.

Authors:  Ha Won Lee; Samia Q Khan; Mohd Hafeez Faridi; Changli Wei; Nicholas J Tardi; Mehmet M Altintas; Hatem A Elshabrawy; Steve Mangos; Kevin L Quick; Sanja Sever; Jochen Reiser; Vineet Gupta
Journal:  J Am Soc Nephrol       Date:  2015-04-09       Impact factor: 10.121

8.  Hydroxyfasudil-mediated inhibition of ROCK1 and ROCK2 improves kidney function in rat renal acute ischemia-reperfusion injury.

Authors:  Dominik Kentrup; Stefan Reuter; Uta Schnöckel; Alexander Grabner; Bayram Edemir; Hermann Pavenstädt; Otmar Schober; Michael Schäfers; Eberhard Schlatter; Eckhart Büssemaker
Journal:  PLoS One       Date:  2011-10-21       Impact factor: 3.240

9.  Pharmacological targeting of actin-dependent dynamin oligomerization ameliorates chronic kidney disease in diverse animal models.

Authors:  Mario Schiffer; Beina Teng; Changkyu Gu; Valentina A Shchedrina; Marina Kasaikina; Vincent A Pham; Nils Hanke; Song Rong; Faikah Gueler; Patricia Schroder; Irini Tossidou; Joon-Keun Park; Lynne Staggs; Hermann Haller; Sergej Erschow; Denise Hilfiker-Kleiner; Changli Wei; Chuang Chen; Nicholas Tardi; Samy Hakroush; Martin K Selig; Aleksandr Vasilyev; Sandra Merscher; Jochen Reiser; Sanja Sever
Journal:  Nat Med       Date:  2015-05-11       Impact factor: 53.440

10.  Activation of Rac-1 and RhoA contributes to podocyte injury in chronic kidney disease.

Authors:  Andrea Babelova; Felix Jansen; Kerstin Sander; Matthias Löhn; Liliana Schäfer; Christian Fork; Hartmut Ruetten; Oliver Plettenburg; Holger Stark; Christoph Daniel; Kerstin Amann; Hermann Pavenstädt; Oliver Jung; Ralf P Brandes
Journal:  PLoS One       Date:  2013-11-07       Impact factor: 3.240

View more
  1 in total

Review 1.  MRTF: Basic Biology and Role in Kidney Disease.

Authors:  Maria Zena Miranda; Zsuzsanna Lichner; Katalin Szászi; András Kapus
Journal:  Int J Mol Sci       Date:  2021-06-03       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.